Citizens has reiterated a Market Outperform rating on Hinge Health Inc (NYSE: HNGE), preserving a $65.00 price target that implies roughly a 97% upside from the stock's trading price of $33.05. The firm's stance aligns with a wider analyst consensus that continues to favor the company, with street targets spanning $48 to $72 and an aggregate recommendation characterized as a strong buy.
Analyst rationale
Citizens pointed to what it described as "impressive results" and said Hinge Health's initial guidance for 2026 demonstrates greater efficiency than some more scaled vertical software businesses. The firm emphasized that, according to InvestingPro data, analysts now expect Hinge Health to reach profitability this year while forecasting 47% revenue growth, even though the company was not profitable over the trailing twelve months.
Key competitive strengths highlighted by Citizens include Hinge Health's role as the preferred musculoskeletal (MSK) provider for major payers and pharmacy benefit managers (PBMs) in the United States, a developing data moat, and progress on the company's HingeSelect marketplace. The firm also noted a "meaningful number of competitive conversions" in 2025 and suggested the company could capture additional clients from competitors Kaia and Sword.
In its modelling, Citizens pointed to the company's 25% initial revenue guidance and projected a 32% free cash flow margin, framing Hinge Health as offering "a rare combination of growth and profitability in what is still a largely greenfield market."
Recent financial performance
Hinge Health reported a robust finish to fiscal 2025. For the fourth quarter, the company delivered earnings per share of $0.49, beating the consensus forecast of $0.14 by 250%. Revenue for the quarter reached $171 million, an increase of 46% from the same period a year earlier.
Following those results, Needham reiterated a Buy rating and kept a $59.00 price target. Needham cited the strong fourth-quarter performance and the better-than-expected initial guidance for fiscal 2026 in affirming its view that Hinge Health is emerging as a significant participant within the digital health landscape.
Implications and context
Analysts' expectations for profitability this year, combined with double-digit revenue growth and the cited efficiency in initial guidance, underpin the bullish analyst tone. Citizens' emphasis on payor and PBM relationships, a growing data moat, and marketplace progress points to the firm's view that Hinge Health's competitive positioning could support further commercial momentum and margin expansion.
These developments reinforce market attention on Hinge Health's role in musculoskeletal care and digital physical therapy, where gains in client conversions and marketplace traction are central to the company's growth and margin story.